I think the CEO is blind to the data until it's locked and analyzed. Until then, he's subject to the pandering of the underlings that want to keep their jobs so they sell him pie in the sky.
I'm not expecting anything actual positive news that will drive the stock. I don't see the point in asking the question. I can't say that I truly understand why people get in a fuss over solid stocks missing some yahoo's projections by $0.02. But we can expect some forward looking statements.
Forward looking statements?
I'm hoping for milestone payments from meeting primary endpoint and forward looking statement of milestone payment for FDA approval.
Does anyone have a statistic for a company having X number of Phase III trials for one drug and success rate? In Oncology?
There is likely a milestone payment for phase III meeting primary endpoint. There is likely a milestone payment for FDA approval of Cobi which can be expected in 6-12 month time frame.
Did you see the headline for ARIA on the same day? "ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today"
It seems that someone is desperate to be right... Post the same headline for 25 pharmaceuticals and you'll get one of them right. Maybe...
Roche would have to make an offer with the other contracts in mind. Personally, I don't think a takeover bid is likely at this point because of that. They would not to be able to suck up the others 100%. The best they could do is buy the program along with cabo; but, I don't see why that would be in the interest of EXEL unless finances became too strained for their cabo trials and/or institutional investors become too weary.
It's still gong to be 6-12 months for FDA approval which is perfect for me since I'd rather have 15% federal tax on this than 40% tax.
What was the milestone payment for phase III achieving primary endpoint?
What is the milestone payment for FDA approval?
Would they really need an offering now? I'm doubting it.
Because cobimetinib met primary endpoint and they're filling with the FDA which upon approval makes this company worth at least $5.
For a doctor to use it off label would put the doctor at significant risk considering the patient is likely to die. Doing something out of common procedure and under FDA guides, would be a job killer.
I like how they equated the open to close of the previous day to the open of today.
Don't bet the farm on EXEL. IMO, they have $5 in the pocket. $25 on a good day.
Breast cancer is huge. Multibillion off the top. EXEL has to piecemeal a Billion let alone a few billion. Though, with their various trials, they could but it would not be overnight.
Though, it's possible that a short squeeze shoots us past a rational realm. It might be worth to sell and repurchase after the volume drops.
It all happened from 3:20 to 4:00 with an potentially unrelated block at 2:49.
I'm suspicious of automated trading picking a trend here. It was coming to the 4th day closing positive.